查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024193

全基因組和EXOME定序市場：按應用、物種、產品和全基因組/EXOME序分類－面向高階主管和顧問的指南，直接面對消費者 (DTC) 分析－第 7 版－（2026-2030 年）

Whole Genome and Exome Sequencing Markets by Application, Organism, Product, and Whole/Exome with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 7th Edition. 2026 To 2030
出版日期: | 出版商: Howe Sound Research | 英文 685 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

報告摘要：

全基因組定序 (WGS) 是一種基因組分析技術，用於確定生物體在特定時間點的整個基因組的 DNA 序列。在人類中，WGS 分析約 30 億個鹼基對，提供基因轉錄區區和非編碼區遺傳變異的全面資訊。與專注於特定基因或基因組區域的標靶定序方法不同，WGS 可以無偏地捕獲遺傳變異，從而能夠識別單核苷酸多態性、插入和缺失、拷貝數變異、結構變異和其他基因組變異。

過去十年，由於次世代定序（NGS）技術的進步，全基因組定序（WGS）市場顯著擴張，NGS技術降低了人類基因組定序的成本和所需時間。目前，全球WGS市場規模估計為每年28.4億美元，預計2030年將達到74億美元，年複合成長率（CAGR）為21.1%。

全基因組定序（WGS）市場的成長與精準醫療的日益普及、基因組檢測臨床應用的不斷擴展以及基因組數據在藥物研發中日益廣泛的應用密切相關。 WGS正擴大應用於腫瘤學、罕見疾病診斷、生殖醫學檢測、感染疾病監測和群體基因組學研究等領域。

技術概述

全基因組定序通常使用能夠並行處理數百萬至數十億個DNA片段的次世代定序平台進行。定序流程通常包括DNA萃取、樣品製備、定序反應和生物資訊分析。

目前，短讀長定序因其高精度和相對較低的單鹼基成本而成為應用最廣泛的定序技術。該技術能夠產生大量的短DNA序列讀段，然後透過電腦將這些讀段組裝起來以重建基因組。

長讀長定序技術正逐漸成為一種補充技術，能夠提高檢測基因組結構變異和重複序列的準確性。長讀長定序技術有望改善短讀長定序方法難以分析的基因組區域的特性。

定序化學製程、自動化和生物資訊學的進步提高了定序處理能力並降低了定序成本。樣品製備流程的自動化提高了可重複性並減少了所需工作量。

基於雲端的生物資訊工具的使用越來越普遍，用於支持大規模基因組資料集的管理和定序結果的解釋。

臨床應用

全基因測序）廣泛應用於臨床領域。在腫瘤學領域，WGS可以辨識與腫瘤發生發展相關的基因突變。全面的基因組分析有助於發現可指導標靶治療的突變。

罕見疾病的診斷是另一個重要的應用領域。許多罕見疾病是由遺傳因素引起的，全基因組定序（WGS）有助於識別導致疾病症狀的致病突變，尤其是在常規診斷方法無法確定病因的情況下。

在生殖醫學領域的應用包括帶因者篩檢和胚胎著床前遺傳學檢測，它們利用基因組資訊來評估遺傳疾病的風險。

在藥物基因體學的應用中，基因組資訊被用來預測患者的藥物反應，並幫助確定合適的劑量。

在感染疾病監測中，基因組定序用於監測病原體的演變並識別新出現的變種。

群體基因組研究涉及對大量個體的定序進行分析，以支持對導致疾病風險的遺傳因素的研究。

市場促進因素

推動全基因組定序市場成長的因素有很多。

定序成本的降低使得基因組檢測在研究和臨床應用上都更容易普及。

精準醫療方法的日益普及，催生了對全面基因組數據的需求，以指導治療決策。

基因組數據在藥物研究中的日益普及，正在加速藥物標靶的識別和生物標記的發現。

政府資助的人口基因組研究舉措正在催生對大規模定序計畫的需求。

生物資訊工具的進步提高了基因組數據的解讀能力，並正在加速其在臨床環境中的應用。

醫療專業人員和患者對基因檢測的認知不斷提高，推動了需求的成長。

基因組資料庫的擴展正在加深我們對基因與疾病之間關係的理解。

市場區隔

WGS市場可以按產品類型、應用程式、最終用戶和地區進行細分。

按產品類型分類，定序設備佔了相當大的佔有率，而定序試劑等耗材則貢獻了大部分的持續收入。生物資訊軟體和定序服務也是重要的組成部分。

就應用領域而言，腫瘤學是最大的應用領域之一，因為基因組分析在癌症治療中至關重要。罕見疾病診斷和生殖醫學檢測也是重要的應用領域。

最終用戶包括學術研究機構、醫院檢查室、製藥公司、生物技術公司和受託研究機構。

北美是最大的區域市場，這得益於其強大的基因組研究基礎設施和精準醫療技術的廣泛應用。隨著基因組研究投資的增加，歐洲和亞太市場也不斷擴張。

競爭格局

WGS市場包括定序平台製造商、試劑供應商、定序服務供應商和生物資訊公司。

競爭的驅動力在於定序準確性、通量、成本效益和數據分析能力的提升。

各公司正擴大提供定序設備、耗材和生物資訊工具結合的整合解決方案。

定序技術提供者與製藥公司之間的策略夥伴關係很常見，尤其是在生物標記發現和臨床試驗應用領域。

取得大規模基因組資料集正成為關鍵的競爭優勢。

資金需求和智慧財產權的考量意味著進入障礙仍然很高。

未來展望

隨著定序技術更廣泛地融入醫療保健系統和調查計畫中，全基因組定序市場預計將繼續擴張。

定序成本的降低可能會進一步推動全基因測序在常規臨床實踐中的應用。

人工智慧和生物資訊工具的進步有望提高基因組數據的解讀能力。

長讀長定序技術可望提高檢測結構變異和複雜基因組區域的準確性。

人口基因組研究計畫有可能擴大基因組數據在預防醫學的應用。

將基因組數據整合到電子健康記錄中，有可能加速個人化治療方法的發展。

整體而言，全基因測序是一項基礎技術，支援精準醫療、生物醫學研究和藥物研發。隨著技術的不斷創新和臨床應用的不斷拓展，預計市場將持續成長。

目錄

第1章 市集指南

  • 全基因組定序市場—策略情勢分析
  • 企業主管、行銷負責人、銷售負責人和業務拓展負責人。
  • 管理顧問和投資顧問指南
  • 人工智慧對全基因組定序（WGS）的影響

第2章：引言與市場定義

  • 本報告中全基因組定序的定義
  • 基因組革命
  • 市場定義
  • 調查方法
  • 展望：醫療保健和體外診斷產業
  • 基因組大小——並非您想像的那樣
  • 全球高通量定序設施列表 - 位置和聯絡方式

第3章 市場概覽

  • 每家參與企業都扮演著不同的角色。
    • 測量儀器製造商
    • 獨立研究機構（專業/專業）
    • 獨立研究機構（國內/區域）
    • 獨立實驗室分析
    • 國家研究機構
    • 醫院檢查室
    • 醫生的檢查室
    • DTC實驗室
    • 定序實驗室
    • 審計機構
  • 全基因組定序分析—市場、案例研究與洞察
    • 直接面對消費者銷售—兩種方法
    • 研究與市場
    • 臨床－了解細胞株和體細胞株
    • 病原體檢測
    • 農業生物技術－大企業
  • 產業結構
    • 醫院檢測共享
    • 規模經濟
    • 測量儀器製造商的作用
    • 對醫療產業的影響—仍面臨許多困難

第4章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 序列分析儀

第5章：WGES的最新進展

第6章：主要企業概況

  • 10x Genomics, Inc.
  • 1928 Diagnostics
  • 23andME Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agilent/Dako
  • Akonni Biosystems
  • Amoy Diagnostics Co., Ltd.
  • Ancestry.com LLC
  • Anchor Dx
  • ARUP Laboratories
  • BaseClear
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • C2i Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • CosmosID
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics.
  • Diasorin SpA
  • Element Biosciences
  • Element Biosciences
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Fabric Genomics
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fulgent Genetics
  • GE Global Research
  • Gencove
  • Genedrive
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetron Holdings
  • Genewiz
  • Genomics England
  • Genomics Personalized Health（GPH）
  • GenomOncology
  • Genzyme Corporation
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helix OpCo
  • Helomics
  • Hologic
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Lunglife AI Inc
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech（Thermo Fisher）
  • Mesa Laboratories, Inc.
  • miR Scientific
  • MNG Labs
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New England Biolabs, Inc.
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • Oncocyte
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Pathogenomix
  • PathoQuest SA
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • QuantuMDx
  • Regeneron Pharmaceuticals
  • Revvity
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • SkylineDx
  • Standard BioTools
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics
  • Ultima Genomics
  • Variantyx
  • Volition
  • Vyant Bio
  • Zymo Research Corp

第7章：全球全基因體定序市場

  • 全球各國市場概覽
  • 全球市場概覽（按應用領域分類）
  • 全球生物物種市場概覽
  • 全球市場概覽（按產品類別分類）
  • 全基因組/EXOME定序全球市場概覽

第8章：全球全基因組定序市場（按應用領域分類）

  • 研究
  • 臨床 - 人類
  • 臨床 - 人體快速
  • 臨床腫瘤學
  • 臨床 - 病原體
  • D2C
  • 農業/其他

第9章：全球全基因組定序市場（按物種分類）

  • 人類
  • 病原
  • 其他

第10章：全球全基因組定序市場（依產品分類）

  • 裝置
  • 試劑
  • 分析
  • 軟體及其他

第11章：全球全基因組定序市場（依全基因組/EXOME定序分類）

  • 全基因組
  • 僅外EXOME
  • 其他/混合

第12章：全基因組定序的未來

第13章附錄

表格一覽

圖表清單

簡介目錄
Product Code: GENWHOLE 426

Report Overview:

Whole Genome Sequencing (WGS) refers to a genomic testing approach that determines the complete DNA sequence of an organism's genome at a single point in time. In humans, WGS analyzes approximately three billion base pairs, providing comprehensive information about genetic variation across both coding and non-coding regions of the genome. Unlike targeted sequencing methods that focus on specific genes or genomic regions, WGS provides an unbiased view of genetic variation, enabling identification of single nucleotide variants, insertions and deletions, copy number variations, structural variants, and other genomic alterations.

The Whole Genome Sequencing market has expanded significantly over the past decade as advances in next-generation sequencing (NGS) technologies have reduced the cost and time required to sequence human genomes. The global WGS market is currently estimated to be USD 2.84 billion annually and is expected to grow at compound annual growth rates of 21.1% over to 2030, reaching 7.4 Billion.

Growth in the WGS market is closely linked to increasing adoption of precision medicine, expanding clinical applications of genomic testing, and growing use of genomic data in pharmaceutical research and drug development. WGS is increasingly used in oncology, rare disease diagnosis, reproductive health testing, infectious disease surveillance, and population genomics initiatives.

Technology Overview

Whole genome sequencing is typically performed using next-generation sequencing platforms capable of processing millions to billions of DNA fragments in parallel. Sequencing workflows generally include DNA extraction, library preparation, sequencing reactions, and bioinformatics analysis.

Short-read sequencing technologies currently represent the most widely used approach due to high accuracy and relatively low cost per base. These technologies generate large numbers of short DNA sequence reads that are computationally assembled to reconstruct the genome.

Long-read sequencing technologies are emerging as complementary approaches that enable improved detection of structural genomic variations and repetitive sequences. Long-read technologies may provide improved characterization of genomic regions that are difficult to analyze using short-read methods.

Advances in sequencing chemistry, automation, and bioinformatics have improved throughput and reduced sequencing costs. Automation of library preparation workflows has improved reproducibility and reduced labor requirements.

Cloud-based bioinformatics tools are increasingly used to manage large genomic datasets and support interpretation of sequencing results.

Clinical Applications

Whole genome sequencing is used across a wide range of clinical applications. In oncology, WGS can identify genetic mutations associated with tumor development and progression. Comprehensive genomic profiling may identify actionable mutations that guide selection of targeted therapies.

Rare disease diagnosis represents another important application area. Many rare diseases have genetic origins, and WGS can help identify pathogenic variants responsible for disease symptoms, particularly in cases where previous diagnostic tests have failed to identify a cause.

Reproductive health applications include carrier screening and preimplantation genetic testing, where genomic information is used to assess risk of inherited disorders.

Pharmacogenomics applications use genomic information to predict patient response to medications and guide dosing decisions.

Infectious disease surveillance uses genomic sequencing to monitor pathogen evolution and identify emerging variants.

Population genomics initiatives involve sequencing large numbers of individuals to support research into genetic contributions to disease risk.

Market Drivers

Several factors are driving growth in the WGS market.

Declining sequencing costs are increasing accessibility of genomic testing for both research and clinical applications.

Increasing adoption of precision medicine approaches is creating demand for comprehensive genomic data to guide treatment decisions.

Growing use of genomic data in pharmaceutical research is supporting drug target identification and biomarker discovery.

Government-funded population genomics initiatives are generating demand for large-scale sequencing projects.

Advances in bioinformatics tools are improving interpretation of genomic data and supporting clinical adoption.

Increasing awareness of genetic testing among healthcare providers and patients is supporting demand growth.

Expansion of genomic databases is improving understanding of gene-disease relationships.

Market Segmentation

The WGS market can be segmented by product type, application, end user, and geographic region.

By product type, sequencing instruments represent an important segment, while consumables such as sequencing reagents represent a significant portion of recurring revenue. Bioinformatics software and sequencing services also represent important segments.

By application, oncology represents one of the largest segments due to importance of genomic profiling in cancer treatment. Rare disease diagnostics and reproductive health testing also represent significant application areas.

End users include academic research institutions, hospital laboratories, pharmaceutical companies, biotechnology companies, and contract research organizations.

North America represents the largest geographic market due to strong genomics research infrastructure and adoption of precision medicine technologies. Europe and Asia-Pacific markets are also expanding as investment in genomic research increases.

Competitive Landscape

The WGS market includes sequencing platform manufacturers, reagent suppliers, sequencing service providers, and bioinformatics companies.

Competition is driven by improvements in sequencing accuracy, throughput, cost efficiency, and data analysis capabilities.

Companies are increasingly offering integrated solutions combining sequencing instruments, consumables, and bioinformatics tools.

Strategic partnerships between sequencing technology providers and pharmaceutical companies are common, particularly in biomarker discovery and clinical trial applications.

Access to large genomic datasets is becoming an important competitive differentiator.

Barriers to entry remain significant due to capital requirements and intellectual property considerations.

Future Outlook

The WGS market is expected to continue expanding as sequencing technologies become more widely integrated into healthcare systems and research programs.

Declining sequencing costs may support broader adoption of whole genome sequencing in routine clinical practice.

Advances in artificial intelligence and bioinformatics tools are expected to improve interpretation of genomic data.

Long-read sequencing technologies may improve detection of structural variants and complex genomic regions.

Population genomics initiatives may increase use of genomic data in preventive medicine.

Integration of genomic data into electronic health records may support personalized treatment approaches.

Overall, whole genome sequencing represents a foundational technology supporting precision medicine, biomedical research, and drug development. Continued technological innovation and expanding clinical applications are expected to support sustained market growth.

Table of Contents

1 Market Guides

  • 1.1 Whole Genome Sequencing Market - Strategic Situation Analysis
    • 1.1.1 Strategic Importance in Precision Medicine
    • 1.1.2 Cost Reduction and Economic Value Challenges
    • 1.1.3 Data Interpretation and Bioinformatics Bottlenecks
    • 1.1.4 Technology Innovation and Platform Competition
    • 1.1.5 Regulatory and Ethical Considerations
    • 1.1.6 Clinical Adoption and Workflow Integration
    • 1.1.7 Dependence on Pharmaceutical and Research Markets
    • 1.1.8 Competitive Landscape and Industry Structure
    • 1.1.9 Geographic Market Dynamics
    • 1.1.10 Outlook and Strategic Implications
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors
  • 1.4 Impact of Artificial Intelligence on WGS

2 Introduction and Market Definition

  • 2.1 Whole Genome Sequencing Definition In This Report
    • 2.1.1 Whole and Exome Sequencing
    • 2.1.2 Research
    • 2.1.3 Clinical Human
    • 2.1.4 Clinical Human Rapid
    • 2.1.5 Clinical Tumor
    • 2.1.6 Clinical Pathogen
    • 2.1.7 Agri/Other
    • 2.1.8 Direct to Consumer
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics
  • 2.6 Sizing the Genome - Not What You Think
    • 2.6.1 Cost, Price and Genome Size, Pricing Practice
  • 2.7 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3 Market Overview

  • 3.1 Market Participants Play Different Roles
    • 3.1.1 Instrument Manufacturer
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 DTC Lab
    • 3.1.9 Sequencing Labs
    • 3.1.10 Audit body
  • 3.2 Whole Genome Sequencing - Markets, Examples and Discussion
    • 3.2.1 Direct to Consumer - Two Approaches
      • 3.2.1.1 The New Age of Medical Information
      • 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 3.2.1.3 Newborn and Prenatal - A Brave New World
      • 3.2.1.4 DTC - How Many Segments?
    • 3.2.2 Research Markets
      • 3.2.2.1 Research Funding and Capital Expense
      • 3.2.2.2 WGS Datasets Preferred
      • 3.2.2.3 Existing research repurposed
      • 3.2.2.4 Organism Wide Market
      • 3.2.2.5 Service Suppliers Respond
    • 3.2.3 Clinical - Understanding Germline and Somatic
      • 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 3.2.4 Pathogen Testing
      • 3.2.4.1 The Hepatitis C Story
      • 3.2.4.2 Will the Microbiology Department Disappear?
    • 3.2.5 AgriBio - Big Business
      • 3.2.5.1 GMO is Here to Stay
      • 3.2.5.2 WGS Benefits and Risks
      • 3.2.5.3 The New Agriculture
  • 3.3 Industry Structure
    • 3.3.1 Hospital's Testing Share
    • 3.3.2 Economies of Scale
    • 3.3.3 Instrument Manufacturer Role
    • 3.3.4 Healthcare Industry Impacts - Still Struggling
      • 3.3.4.1 Can the Healthcare Industry Adapt?
      • 3.3.4.2 Genetic Counselling as an Industry
      • 3.3.4.3 WGES Adoption and Cannibalization
      • 3.3.4.4 The Meaning of Grail

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Diagnostic Factors
    • 4.1.2 Interpreting the Code Otherwise
    • 4.1.3 Changes in Agriculture
    • 4.1.4 Fertility Technology Comes of Age
    • 4.1.5 Pathogen Challenges
  • 4.2 Factors Limiting Growth
    • 4.2.1 Increased Competition Lowers Price
    • 4.2.2 Lower Costs
    • 4.2.3 Healthcare Cost Concerns Curtail Growth
    • 4.2.4 Wellness has a downside
    • 4.2.5 GMO Opposition Movement
  • 4.3 Sequencing Instrumentation
    • 4.3.1 Instrumentation Tenacity
    • 4.3.2 Declining Cost Changes Industry Structure
    • 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 4.3.4 Illumina
    • 4.3.5 ION
    • 4.3.6 Pacific Biosystems
    • 4.3.7 Roche 454
    • 4.3.8 SOLiD
    • 4.3.9 Oxford Nanopore
      • 4.3.9.1 What is Oxford Nanopore Sequencing?
      • 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
      • 4.3.9.3 Oxford Nanopore Products
    • 4.3.10 Long Reads - Further Segmentation
    • 4.3.11 Linked Reads
    • 4.3.12 Targeted Sequencing Adopts CRISPR
    • 4.3.13 New Sequencing Technologies
      • 4.3.13.1 RNAP sequencing
      • 4.3.13.2 In vitro virus high-throughput sequencing
      • 4.3.13.3 Tunnelling currents DNA sequencing
      • 4.3.13.4 Sequencing by hybridization
      • 4.3.13.5 Sequencing with mass spectrometry
      • 4.3.13.6 Microfluidic Sanger sequencing
      • 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 GeneDx to Acquire Fabric Genomics
  • 5.3 WGS provides faster detection of Salmonella
  • 5.4 UltraRapid WGS, Results in 48 Hours
  • 5.5 WGS Identifies Desirable Tobacco Genes
  • 5.6 The Case for WGS use in All Blood Cancers
  • 5.7 $400 Personal WGS
  • 5.8 Incorporating WGS into Cancer Care
  • 5.9 Epic, GeneDx to broaden WGS potential
  • 5.10 Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
  • 5.11 WGS Uncovers Genetic causes of cerebral palsy
  • 5.12 Rapid WGS Use recommended for Intensive Care
  • 5.13 Quest and Ultima Genomics to Develop Tests
  • 5.14 WHO launches WGS Guide
  • 5.15 Myriad Genetics to Study MRD Testing
  • 5.16 Adela Developing Epigenetic Multi-Cancer Detection
  • 5.17 Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
  • 5.18 Bionano Laboratories Announces New Prenatal Whole Genome Tests
  • 5.19 Myriad Genetics Plans Product Launches
  • 5.20 Genomics England, Aims to Sequence 100K Newborns
  • 5.21 Juno Diagnostics NIPT With At-Home Sample Collection
  • 5.22 Cardio Diagnostics Launches Genetic Cardio Risk Test
  • 5.23 Universal Genetic Testing in Breast Cancer Further Supported
  • 5.24 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
  • 5.25 MyOme Lands Investment for WGS
  • 5.26 GenomSys Gains CE Mark for New Genomic Analysis Software
  • 5.27 WGS Finds Lung Cancers Fall Into Molecular Subtypes
  • 5.28 Testing Distinguishes Benign Tumors From Precancerous Condition
  • 5.29 Plan to Sequence All Newborns in UK
  • 5.30 Clear Labs Raises $60M for Nanopore Sequencing
  • 5.31 Variantyx Expands Into Prenatal, Cancer Testing
  • 5.32 Whole-Genome Sequencing Aids Diagnosis in Stockholm
  • 5.33 Variantyx Raises $20M
  • 5.34 Nonacus WGS Service for SARS-CoV-2 Laboratories
  • 5.35 Center to Report Risk Scores in Clinical WGS
  • 5.36 Stanford Launches WGS for Cardiovascular Testing
  • 5.37 Illumina and NY Healthcare Partner on Clinical WGS
  • 5.38 Increased Adoption of WGS Needs Acceptance by Payors, Providers
  • 5.39 Veritas Intercontinental Completes Euro 5M Series B Financing Round
  • 5.40 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
  • 5.41 Genomics England Adopts Quantum ActiveScale Object Storage
  • 5.42 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
  • 5.43 NHS Wales Introduces WGS for Critically Ill Newborns
  • 5.44 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
  • 5.45 C2i Genomics to Launch Trials for MRD Detection Tech
  • 5.46 Roche Acquires Sequencing Company Stratos Genomics
  • 5.47 UK COVID-19 Sequencing Consortium Launches
  • 5.48 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
  • 5.49 Experience From Centralized Genomic Medicine Lab
  • 5.50 MGI to Enable $100 Human Genome
  • 5.51 Nebula Genomics offers $299 WGS
  • 5.52 Team to Study Campylobacter Omics
  • 5.53 Veritas Genetics Restarts US Business
  • 5.54 NEOGEN, Gencove partner to advance animal genomics

6 Profiles of Key Companies

  • 6.1 10x Genomics, Inc.
  • 6.2 1928 Diagnostics
  • 6.3 23andME Inc.
  • 6.4 Abbott Laboratories
  • 6.5 AccuraGen Inc.
  • 6.6 Adaptive Biotechnologies
  • 6.7 Admera Health, LLC
  • 6.8 Agilent/Dako
  • 6.9 Akonni Biosystems
  • 6.10 Amoy Diagnostics Co., Ltd.
  • 6.11 Ancestry.com LLC
  • 6.12 Anchor Dx
  • 6.13 ARUP Laboratories
  • 6.14 BaseClear
  • 6.15 Baylor Miraca Genetics Laboratories
  • 6.16 Beckman Coulter Diagnostics
  • 6.17 Becton, Dickinson and Company
  • 6.18 BGI Genomics Co. Ltd
  • 6.19 Bioarray Genetics
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 BioGenex
  • 6.24 Biolidics Ltd
  • 6.25 bioMerieux Diagnostics
  • 6.26 Bioneer Corporation
  • 6.27 Bio-Rad Laboratories, Inc
  • 6.28 Bio-Techne
  • 6.29 C2i Genomics
  • 6.30 Caris Molecular Diagnostics
  • 6.31 CellMax Life
  • 6.32 Centogene
  • 6.33 Circulogene
  • 6.34 Clear Labs
  • 6.35 Clinical Genomics
  • 6.36 Complete Genomics, Inc. - A BGI Company
  • 6.37 CosmosID
  • 6.38 Dante Labs
  • 6.39 Datar Cancer Genetics Limited
  • 6.40 Day Zero Diagnostics.
  • 6.41 Diasorin S.p.A.
  • 6.42 Element Biosciences
  • 6.43 Element Biosciences
  • 6.44 Epic Sciences
  • 6.45 Epigenomics AG
  • 6.46 Eurofins Scientific
  • 6.47 Excellerate Bioscience
  • 6.48 Fabric Genomics
  • 6.49 Freenome
  • 6.50 FUJIFILM Wako Diagnostics
  • 6.51 Fulgent Genetics
  • 6.52 GE Global Research
  • 6.53 Gencove
  • 6.54 Genedrive
  • 6.55 GeneDx Holdings
  • 6.56 GeneFirst Ltd.
  • 6.57 Genetron Holdings
  • 6.58 Genewiz
  • 6.59 Genomics England
  • 6.60 Genomics Personalized Health (GPH)
  • 6.61 GenomOncology
  • 6.62 Genzyme Corporation
  • 6.63 Grifols
  • 6.64 Guardant Health
  • 6.65 Guardiome
  • 6.66 HeiScreen
  • 6.67 Helix
  • 6.68 Helix OpCo
  • 6.69 Helomics
  • 6.70 Hologic
  • 6.71 HTG Molecular Diagnostics
  • 6.72 Human Longevity, Inc.
  • 6.73 iCellate
  • 6.74 Illumina
  • 6.75 Incell Dx
  • 6.76 Inivata
  • 6.77 Invitae Corporation
  • 6.78 Invivoscribe
  • 6.79 Karius
  • 6.80 Lunglife AI Inc
  • 6.81 Macrogen
  • 6.82 MDNA Life SCIENCES, Inc.
  • 6.83 MDx Health
  • 6.84 Medgenome
  • 6.85 Meridian Bioscience
  • 6.86 Mesa Biotech (Thermo Fisher)
  • 6.87 Mesa Laboratories, Inc.
  • 6.88 miR Scientific
  • 6.89 MNG Labs
  • 6.90 NantHealth, Inc.
  • 6.91 Natera
  • 6.92 Nebula Genomics
  • 6.93 NeoGenomics
  • 6.94 New England Biolabs, Inc.
  • 6.95 Novogene Bioinformatics Technology Co., Ltd.
  • 6.96 Omega Bioservices
  • 6.97 Oncocyte
  • 6.98 OncoDNA
  • 6.99 OpGen
  • 6.100 ORIG3N, Inc.
  • 6.101 Origene Technologies
  • 6.102 Oxford Nanopore Technologies
  • 6.103 Pacific Biosciences
  • 6.104 Panagene
  • 6.105 Pathogenomix
  • 6.106 PathoQuest S.A.
  • 6.107 Personal Genome Diagnostics
  • 6.108 Personalis
  • 6.109 Precipio
  • 6.110 PrecisionMed
  • 6.111 Promega
  • 6.112 Protagen Diagnostics
  • 6.113 Qiagen
  • 6.114 QuantuMDx
  • 6.115 Regeneron Pharmaceuticals
  • 6.116 Revvity
  • 6.117 Roche Molecular Diagnostics
  • 6.118 Roswell Biotechnologies
  • 6.119 Seegene
  • 6.120 Sequencing.com
  • 6.121 Siemens Healthineers
  • 6.122 simfo GmbH
  • 6.123 Singlera Genomics Inc.
  • 6.124 Singular Genomics
  • 6.125 SkylineDx
  • 6.126 Standard BioTools
  • 6.127 Sure Genomics, Inc.
  • 6.128 Sysmex
  • 6.129 Sysmex Inostics
  • 6.130 Tempus Labs, Inc.
  • 6.131 Thermo Fisher Scientific Inc.
  • 6.132 Ultima Genomics
  • 6.133 Ultima Genomics
  • 6.134 Variantyx
  • 6.135 Volition
  • 6.136 Vyant Bio
  • 6.137 Zymo Research Corp

7 The Global Market for Whole Genome Sequencing

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Application - Overview
    • 7.2.1 Table - Global Market by Application
    • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Application - Base Year
    • 7.2.4 Chart - Global Market by Application - Final Year
    • 7.2.5 Chart - Global Market by Application - Share by Year
    • 7.2.6 Chart - Global Market by Application - Segment Growth
  • 7.3 Global Market by Organism - Overview
    • 7.3.1 Table - Global Market by Organism
    • 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Organism - Base Year
    • 7.3.4 Chart - Global Market by Organism - Final Year
    • 7.3.5 Chart - Global Market by Organism - Share by Year
    • 7.3.6 Chart - Global Market by Organism - Segment Growth
  • 7.4 Global Market by Product - Overview
    • 7.4.1 Table - Global Market by Product
    • 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Product - Base Year
    • 7.4.4 Chart - Global Market by Product - Final Year
    • 7.4.5 Chart - Global Market by Product - Share by Year
    • 7.4.6 Chart - Global Market by Product - Segment Growth
  • 7.5 Global Market by Whole/Exome - Overview
    • 7.5.1 Table - Global Market by Whole/Exome
    • 7.5.2 Chart - Global Market by Whole/Exome - Base/Final Year Comparison
    • 7.5.3 Chart - Global Market by Whole/Exome - Base Year
    • 7.5.4 Chart - Global Market by Whole/Exome - Final Year
    • 7.5.5 Chart - Global Market by Whole/Exome - Share by Year
    • 7.5.6 Chart - Global Market by Whole/Exome - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

  • 8.1 Research
    • 8.1.1 Table Research - by Country
    • 8.1.2 Chart - Research Growth
  • 8.2 Clinical Human
    • 8.2.1 Table Clinical Human - by Country
    • 8.2.2 Chart - Clinical Human Growth
  • 8.3 Clinical Human Rapid
    • 8.3.1 Table Clinical Human Rapid - by Country
    • 8.3.2 Chart - Clinical Human Rapid Growth
  • 8.4 Clinical Tumor
    • 8.4.1 Table Clinical Tumor - by Country
    • 8.4.2 Chart - Clinical Tumor Growth
  • 8.5 Clinical Pathogen
    • 8.5.1 Table Clinical Pathogen - by Country
    • 8.5.2 Chart - Clinical Pathogen Growth
  • 8.6 Direct to Consumer
    • 8.6.1 Table Direct to Consumer - by Country
    • 8.6.2 Chart - Direct to Consumer Growth
  • 8.7 Agriculture/Other
    • 8.7.1 Table Agriculture/Other - by Country
    • 8.7.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

  • 9.1 Human
    • 9.1.1 Table Human - by Country
    • 9.1.2 Chart - Human Growth
  • 9.2 Pathogen
    • 9.2.1 Table Pathogen - by Country
    • 9.2.2 Chart - Pathogen Growth
  • 9.3 Other Organism
    • 9.3.1 Table Other Organism - by Country
    • 9.3.2 Chart - Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

  • 10.1 Instruments
    • 10.1.1 Table Instruments - by Country
    • 10.1.2 Chart - Instruments Growth
  • 10.2 Reagents
    • 10.2.1 Table Reagents - by Country
    • 10.2.2 Chart - Reagent Growth
  • 10.3 Analysis
    • 10.3.1 Table Analysis - by Country
    • 10.3.2 Chart - Analysis Growth
  • 10.4 Software & Other
    • 10.4.1 Table Software & Other - by Country
    • 10.4.2 Chart - Software & Other Growth

11 Global Whole Genome Sequencing Markets - by Whole/Exome

  • 11.1 Whole Genome
    • 11.1.1 Table Whole Genome - by Country
    • 11.1.2 Chart - Whole Genome Growth
  • 11.2 Exome Only
    • 11.2.1 Table Exome Only - by Country
    • 11.2.2 Chart - Exome Only Growth
  • 11.3 Other/Mix
    • 11.3.1 Table Other/Mix - by Country
    • 11.3.2 Chart - Other/Mix Growth

12 Vision of the Future of Whole Genome Sequencing

13 Appendices

  • 13.1 United States Medicare System: Laboratory Fees Schedule
  • 13.2 The Most Used IVD Assays
  • 13.3 The Highest Grossing Assays
  • 13.4 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 List of GLOBAL SEQUENCING LOCATIONS
  • Table 4 Market Players by Type
  • Table 5 The Different Markets for Whole Genome Sequencing
  • Table 6 DTC Sub Segments
  • Table 7 Roles of WGS in AgriBio
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10 - Listing of Current NGS Instrument Specifications
  • Table 11 Six New Sequencing Technologies
  • Table 12 - Global Market by Region
  • Table 13 Global Market by Application
  • Table 14 Global Market by Organism
  • Table 15 Global Market by Product
  • Table 16 Global Market by Whole/Exome
  • Table 17 Research by Country
  • Table 18 Clinical Human by Country
  • Table 19 Clinical Human Rapid by Country
  • Table 20 Clinical Tumor by Country
  • Table 21 Clinical Pathogen by Country
  • Table 22 Direct to Consumer by Country
  • Table 23 Agriculture/Other by Country
  • Table 24 Human by Country
  • Table 25 Pathogen by Country
  • Table 26 Other Organism by Country
  • Table 27 Instruments by Country
  • Table 28 Reagents by Country
  • Table 29 Analysis by Country
  • Table 30 Software & Other by Country
  • Table 31 Whole Genome by Country
  • Table 32 Exome Only by Country
  • Table 33 Other/Mix by Country
  • Table 34 Clinical Lab Fee Schedule
  • Table 35 The Most Common Assays
  • Table 36 Largest Revenue Assays

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 Size of Genome for Various Species
  • Figure 4 - Cost To Sequence a Human Genome
  • Figure 5 Base Year Country Market Share Chart
  • Figure 6 Global Market by Application - Base vs. Final Year
  • Figure 7 Global Market by Application Base Year
  • Figure 8 Global Market by Application Final Year
  • Figure 9 Application Type Share by Year
  • Figure 10 by Application Segment Growth
  • Figure 11 by Organism - Base vs. Final Year
  • Figure 12 by Organism Market Base Year
  • Figure 13 by Organism Market Final Year
  • Figure 14 by Organism Share by Year
  • Figure 15 by Organism Segment Growth
  • Figure 16 by Product - Base vs. Final Year
  • Figure 17 by Product Market Base Year
  • Figure 18 by Product Market Final Year
  • Figure 19 by Product Share by Year
  • Figure 20 by Product Segment Growth
  • Figure 21 by Whole/Exome - Base vs. Final Year
  • Figure 22 by Whole/Exome Market Base Year
  • Figure 23 by Whole/Exome Market Final Year
  • Figure 24 by Whole/Exome Share by Year
  • Figure 25 by Whole/Exome Segment Growth
  • Figure 26 Research Growth
  • Figure 27 Clinical Human Growth
  • Figure 28 Clinical Human Growth
  • Figure 29 Clinical Tumor Growth
  • Figure 30 Clinical Pathogen Growth
  • Figure 31 Direct to Consumer Growth
  • Figure 32 Agriculture/Other Growth
  • Figure 33 Human Growth
  • Figure 34 Pathogen Growth
  • Figure 35 Other Organism Growth
  • Figure 36 Instruments Growth
  • Figure 37 Reagent Growth
  • Figure 38 Analysis Growth
  • Figure 39 Software & Other Growth
  • Figure 40 Whole Genome Growth
  • Figure 41 Exome Only Growth
  • Figure 42 Other/Mix Growth